Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But, thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years.